TME Pharma publishes its semi annual results and half-year report Berlin, Germany, October 30, 2025, 21.00am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases, publishes today its semi annual results and half-year report. The first half of the year was marked by TME Pharma's reorganization to a lower-cost outsourced staffing model. The results of this can be seen from H2 onwards, namely ...